Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $40.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 4/3/2025 | $9.00 | Neutral | B. Riley Securities |
| 10/18/2024 | $11.75 | Buy | Berenberg |
| 9/19/2024 | $12.00 | Buy | Alliance Global Partners |
| 10/10/2022 | $9.00 | Outperform → Neutral | Robert W. Baird |
| 10/6/2022 | $13.00 → $9.00 | Outperform → Market Perform | BMO Capital Markets |
| 7/7/2022 | Mkt Perform | JMP Securities | |
| 1/13/2022 | Overweight → Sector Weight | Keybanc |
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), announced today that it intends to release its fourth quarter and year-end 2025 financial results after the market closes on Wednesday, February 25, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, February 26, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Please note, at the time it releases its fourth quarter and year-end 2025 financial results, the Company's previously
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
8-K - Global Medical REIT Inc. (0001533615) (Filer)
8-K - Global Medical REIT Inc. (0001533615) (Filer)
Citizens JMP upgraded Global Medical REIT from Mkt Perform to Mkt Outperform and set a new price target of $40.00
B. Riley Securities resumed coverage of Global Medical REIT with a rating of Neutral and set a new price target of $9.00
Berenberg initiated coverage of Global Medical REIT with a rating of Buy and set a new price target of $11.75
4 - Global Medical REIT Inc. (0001533615) (Issuer)
4 - Global Medical REIT Inc. (0001533615) (Issuer)
4 - Global Medical REIT Inc. (0001533615) (Issuer)
4 - Global Medical REIT Inc. (0001533615) (Issuer)
4 - Global Medical REIT Inc. (0001533615) (Issuer)
4 - Global Medical REIT Inc. (0001533615) (Issuer)
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE") today announced that Ronald Marston has notified the Board of Directors (the "Board") that he plans to retire as a member of the Board at the end of his current term and that the Board has declared the Company's 2025 fourth quarter common and preferred dividends. Ronald Marston's Retirement from Board of Directors Mr. Marston has served on the Board since 2015 as an independent director and at different points throughout his tenure has served as the chair of the Board's Nominating and Corporate Governance Committee as well as a member of the Board's Audit and Compensation Committees. Mr. Marston's retirement will be effective
Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), announced today that it intends to release its fourth quarter and year-end 2025 financial results after the market closes on Wednesday, February 25, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, February 26, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Please note, at the time it releases its fourth quarter and year-end 2025 financial results, the Company's previously
Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE") today announced that the Company will change its name, effective as of 12:01 a.m., Eastern Time, on February 23, 2026, to "Chiron Real Estate Inc." Beginning on February 23, 2026, the Company's common stock will trade on the New York Stock Exchange (the "NYSE") under the new name, "Chiron Real Estate Inc.," and ticker symbol "XRN." "After spending the last six months evaluating and redefining our strategy, we are rebranding to better align with our new mission," Mark Decker, Jr., Chief Executive Officer, said. "Chiron (Kai-ron), a figure from Greek mythology known for his knowledge and skill with medicine, was highly revered a
Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), announced today that information regarding the federal income tax treatment of the dividends paid in 2025 on the Company's Common Stock and Series A Preferred Stock has been posted to the Company's website, at the following link. https://investors.globalmedicalreit.com/stock-data/dividend-tax-information Note: Data for common dividends paid in January, April and July 2025 have been adjusted to reflect the Company's one-for-five reverse stock split that was effective on September 19, 2025. Stockholders should review their Forms 1099 as well as other 2025 tax statements that they will receive from their brokerage firms or o
SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)
SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)
SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)